ARKG is trading 3.4% up today as cooler PCE inflation data and strong technology earnings drive a broad risk-on rally, significantly improving market sentiment toward growth-oriented assets.
- The genomics and biotech sectors are benefiting from lower interest rate expectations and renewed optimism surrounding industry consolidation.
- Sentiment is further bolstered by Argenx’s $2.2 billion acquisition of Forte Biosciences, which highlights the increasing value of innovative autoimmune and genomic therapies.